Platelet-Directed Whole Blood Transfusion Strategy for Malaria — PLATFORM  

Thrombocytopenia Clinical Trial

Official title: Clinical and Translational Investigations of Severe Malaria Pathophysiology [Parent Study Protocol]

Status Recruiting

Clinical Trial Summary

Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.

Clinical Trial Description

The PLATFORM trial is a single-center, open-label randomized controlled trial of whole blood transfusion for severe malaria complicated by thrombocytopenia. The trial will recruit 132 Zambian children 6 months to 15 years old with severe malaria defined according to modified WHO criteria with concomitant thrombocytopenia, defined here as a platelet count ≤75,000/uL, who do not otherwise have a current indication for transfusion according to current guidelines. Children will be randomized 1:1 to whole blood transfusion or no whole blood transfusion and followed to hospital discharge or death. The trial is nested within the Children and Adults with Severe Malaria (CHASM) cohort, a prospective observational study of severe malaria. ;

Related Conditions & MeSH terms

• Malaria
• Severe Malaria
• Thrombocytopenia

• NCT number: NCT05711485
• Study type: Interventional
• Source: Johns Hopkins Bloomberg School of Public Health
• Contact: Matthew M Ippolito, MD PhD
• Phone: 443-287-4809
• Email: mippolito@jhu.edu
• Status: Recruiting
• Phase: N/A
• Start date: February 24, 2024
• Completion date: February 28, 2025